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Abstract
Craniometaphyseal dysplasia (CMD) is a rare sclerosing skeletal disorder with progressive hyperostosis of
craniofacial bones. CMD can be inherited in an autosomal dominant (AD) trait or occur after de novo mutations in the
pyrophosphate transporter ANKH. Although the autosomal recessive (AR) form of CMD had been mapped to
6q21-22 the mutation has been elusive. In this study, we performed whole-exome sequencing for one subject with
AR CMD and identified a novel missense mutation (c.716G>A, p.Arg239Gln) in the C-terminus of the gap junction
protein alpha-1 (GJA1) coding for connexin 43 (Cx43). We confirmed this mutation in 6 individuals from 3 additional
families. The homozygous mutation cosegregated only with affected family members. Connexin 43 is a major
component of gap junctions in osteoblasts, osteocytes, osteoclasts and chondrocytes. Gap junctions are responsible
for the diffusion of low molecular weight molecules between cells. Mutations in Cx43 cause several dominant and
recessive disorders involving developmental abnormalities of bone such as dominant and recessive oculodentodigital
dysplasia (ODDD; MIM #164200, 257850) and isolated syndactyly type III (MIM #186100), the characteristic digital
anomaly in ODDD. However, characteristic ocular and dental features of ODDD as well as syndactyly are absent in
patients with the recessive Arg239Gln Cx43 mutation. Bone remodeling mechanisms disrupted by this novel Cx43
mutation remain to be elucidated.
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Introduction
Craniometaphyseal dysplasia (CMD; MIM #123000) is a rare
genetic disorder affecting the skeleton with progressive
hyperostosis of craniofacial bones and abnormal modeling of
tubular bones. Craniofacial abnormalities include wide-set
eyes, wide nasal bridge, paranasal bossing and prominent
mandible. The main feature leading to morbidity is hyperostosis
of cranial bones, which can lead to increased intracranial
pressure and narrowing of neural foramina [1,2,3,4]. Nerve
damage can lead to facial palsy, blindness and deafness.
Increased bone formation can further lead to Chiari
malformation, compression of the spinal cord and
syringomyelia [5,6,7]. The metaphyses of long bones are
widened and undertrabeculated, possibly due to insufficient
bone remodeling by dysfunctional osteoblasts and osteoclasts
[8,9].
Many CMD cases described so far are inherited as an
autosomal dominant (AD) trait [10,11,12,13] or occur as de
novo mutations [12,13,14,15,16]. Until now all CMD mutations
have been found in the human progressive ankylosis gene
(ANKH). ANKH encodes for a ten-span transmembrane protein
associated with pyrophosphate transport [17]. Most of the
ANKH mutations are located in cytoplasmic domains close to
the C-terminus [12,13]. A CMD knock-in mouse model carrying
a Phe377del mutation in ANKH develops many of the features
that are characteristic for CMD patients and has been shown to
exhibit impaired osteoblastogenesis and osteoclastogenesis
[8,9].
Some pedigrees suggest an autosomal recessive (AR) mode
of transmission [1,18,19,20,21] and a linkage study has
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identified a potential locus for the autosomal recessive form of
CMD within a 7 cM interval on chromosome 6q21-22 [18].
However, a causative variant responsible for AR CMD could
not be identified. Here we report the first gene mutation for
autosomal recessive CMD in the gap junction gene GJA1,




This study was approved by the Institutional Review Board at
UCHC and the Ethics Committees at Kanchi Kamkoti, Childs
Trust Hospital, University of Campinas, Ethics Commission for
Health of the Hospital Center of Lisboa Central and Institute of
Biosciences, University of Sao Paolo. Written informed consent
had been obtained from study participants and parents of
minors. Families and individuals included in this study were
selected based on absence of mutations in ANKH and a
potential recessive inheritance pattern. The data described
here cannot be deposited to a public repository due to issues of
patient confidentiality. Data can be shared with other
investigators upon request and subject to clearance from our
Institutional Review Board.
Whole-Exome Sequencing
Genomic DNA (gDNA) was extracted from blood (Gentra
Puregene; QIAGEN Inc., Valencia, CA) or saliva (OraGene
saliva kit; DNA Genotek Inc., Kanata, Ontario, Canada) and
submitted to Otogenetics Corporation (Norcross, GA USA) for
exome capture and sequencing.
Briefly, gDNA was subjected to agarose gel electrophoresis
and OD ratio tests to confirm the purity and concentration prior
to fragmentation by a Covaris fragmenter (Covaris, Inc.,
Woburn, MA). Fragmented gDNAs were tested for size
distribution and concentration using an Agilent Bioanalyzer
2100 (Agilent Technologies, Santa Clara, CA) and Nanodrop
(Thermo, Fisher Scientific, Pittsburgh, PA). Sequencing
libraries were prepared using NEBNext reagents (New England
Biolabs, Ipswich, MA) and the resulting libraries were subjected
to exome enrichment using the TruSeq Exome Enrichment Kit
(Illumina, Inc., San Diego, CA) following manufacturer’s
instructions. Enriched libraries were tested for enrichment by
qPCR and for size distribution and concentration with Agilent
Bioanalyzer 2100. The samples were then sequenced on an
Illumina HiSeq2000, which generated paired-end reads of 100
nucleotides.
Sequencing Alignment, Variant Calling and Annotation
Alignment and variant calling were evaluated on the
DNAnexus platform (DNAnexus, Inc., Mountain View, CA).
Burrows-Wheeler Aligner (BWA, version 0.5.9-r16) was used to
align the sequence reads to the human reference genome
GRCh37 (hg19). Subsequently, Nucleotide-Level Variation
Analysis was used to identify differences in the sample genome
with respect to the reference genome. Differences include
single- and multi-nucleotide polymorphisms (SNPs, MNPs),
insertions and/or deletions (indels). Resulting variant calls were
first filtered for confidence calls originating from bidirectional
sequence reads using a quality threshold of ≥30 and read
depth ≥10. Variants were then prioritized for further filtering and
retained for further analysis when a variant appeared as a
homozygous and non-synonymous, i.e. altering an amino acid.
Selected variants were then compared to public databases. All
variants present in the dbSNP database (version 135), 1000
Genomes Project and NHLBI Exome Sequencing Project
Exome Variant Server (EVS) were excluded.
Mutation Validation Analysis
Nucleotide changes in the candidate gene CX43 were
numbered corresponding to their position in CX43 mRNA
(Ensembl gene ID: ENSG00000152661). Verification of the c.
716G>A candidate variant was performed by Sanger
sequencing of exon 2 of CX43 using PCR primers GJA1-F (5’-
TTCTGGGTCCTGCAGATCAT-3’) and GJA1-R (5’-
TCTTGATGCTTTCAAGCCTGT-3’) resulting in a 944 bp
product. All available family members were tested for
cosegregation of the candidate variant with the disease
phenotype. PCR products containing the variant of interest
were purified with ExoSAP-IT (Affymetrix, Santa Clara, CA)
and sequenced by Sanger sequencing using ABI PRISM
3730xl DNA Analyzers with standard protocol (Genewiz, South
Plainfield, NJ). The functional effect of a missense variant was
evaluated using in silico prediction tools PolyPhen2, SIFT,
Mutation Taster and SNAP. Sequence alignment among
different species was performed with ClustalW2.
Results and Discussion
We performed exome sequencing on proband VIII5 from the
consanguineous Family 1 (Figure 1) at an average depth of
78x using a TruSeq Exome 62Mb Enrichment kit and
HiSeq2000 sequencer (Illumina). 20,794 genes were targeted
which include 201,121 exons in total. A total of 163,463 genetic
variants, including SNPs and indels were identified. Out of
46,866 homozygous variants 4,895 were non-synonymous.
Only one of these variants, a G to A tansversion (c.716G>A) in
GJA1 (RefSeq NM_000165.3) (Figure 2), which was novel
according to dbSNP, the Human Gene Mutation Database
(HGMD), 1000 Genomes Project (approx. 1,000 individuals)
and National Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project (ESP; approx. 2,200 individuals) data
colocalized with the putative recessive CMD locus on
chromosome 6q21–q22. GJA1 codes for the gap junction alpha
1 protein and is also known as CONNEXIN 43, CX43 (MIM
#121014).
The non-synonymous missense variant in GJA1 resulted in a
homozygous amino acid substitution from Arginine to
Glutamine (p.Arg239Gln; R239Q). This variant was predicted
to be damaging by Mutation Taster and SNAP although SIFT
and PolyPhen2 did not flag this mutation as damaging. The
R239Q variant in CX43 is located in a phylogenetically highly
conserved region, which has also been identified as a potential
tubulin binding motif (Figure 3) [22]. This Arginine is conserved
in 4 other connexins, CX37, (GJA4), CX40 (GJA5), CX30
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(GJB6) and CX32 (GJB1), however, no mutations have been
reported for Arginine at this position.
We then identified this variant in 4 affected individuals (V1
(proband), V4, IV26, IV27) of Brazilian Family 2 [18] and in the
affected child of the Indian Family 3 (III11) by Sanger
sequencing (Figure 2). The c.716G>A variant was absent in the
unaffected sibling of family 1 (VIII3), who had a wild type
genotype. The parents of all probands as well as two
unaffected siblings in Family 2 and one unaffected sibling in
Family 3 were heterozygous for the mutation. We found the
same homozygous c.716G>A mutation in a fourth proband
from Brazil diagnosed with CMD but with unknown family
background (data not shown). The summary of all subject
genotypes is shown in Table S1.
The affected individuals in Family 2 (V1, V4, V26 and IV27)
were born to healthy consanguineous parents and showed
relatively mild symptoms as described before [18] with nasal
flattening and hypertelorism. 3D computed tomography and
radiographs for V1 and V4 showed sclerosis of the cranial vault
and cranial base. Facial bones were hyperostotic. All affected
individuals in this study had difficulties breathing, probably due
to hyperostosis, but none showed loss of vision or hearing loss.
Affected members of this family displayed diaphyseal
hyperostosis in limb bones with mild metaphyseal widening.
Another AR disorder, a form of spondylocostal dysostosis (SD),
also segregates in this family. Subject V3 with SD (indicated as
striped square in Figure 1) showed normal skull and limb
radiographs.
The proband of Family 3 (Figure 1B) is a 3-year-old male
referred to the genetics clinic for epiphora (L) and dysmorphic
facial features. His height was 96 cm (50th centile) and head
circumference was 50 cm (50th–85th centile). He had relative
macrocephaly, hypertelorism, an unusual thick bony wedge
over the bridge of the nose and a depressed and flattened
nasal bridge. The ophthalmological exam revealed secondary
naso-lacrimal duct obstruction (bilateral). X-ray of skull
revealed significant sclerosis of skull base and 3D MRI of
paranasal sinuses and orbits showed bilateral dense sclerotic
thickening in parietal, occipital and ethmoid bones as well as in
the frontal process of maxillary and zygomatic bones. His
serum calcium, phosphorus and serum alkaline phosphate
levels were normal. The proband of Family 1 is unfortunately
lost to follow up and detailed clinical information is no longer
available.
CX43 is a major component of hemichannels and gap
junctions. Two opposing hemichannels form a gap junction
connecting the cytoplasm of neighboring cells to facilitate gap
junctional intercellular communication (GJIC) via exchange of
ions and molecules smaller than 1.2 kDa. The GJA1 gene
consists of 2 exons and encodes a transmembrane protein with
four transmembrane domains (TM), two extracellular loops,
one intracellular loop and intracellular amino- (N-term) and
carboxyl-terminal ends (C-term) (Figure 4). The mutation
identified in this study is located in exon 2 of the CX43 gene
and leads to a substitution in position 239 in the intracellular C-
terminal domain proximal to the fourth transmembrane domain.
At least three connexins, CX43, CX45 and CX46 are
Figure 1.  Pedigree information and case description.  (A) Pedigrees of Families 1, 2 and 3 with mutation in the novel CMD gene
GJA1. Proband DNA from Family 1 was used for exome sequencing (Arrow). (B) Radiographic images of proband for Family 3
show hyperostosis of cranial base and facial bones, femoral flaring and undertrabeculation of metaphyses with dense diaphyseal
bone consistent with findings in Family 2. Diffuse widening of the proximal and medial phalanges are consistent with findings in
CMD patients from Family 2 [18].
doi: 10.1371/journal.pone.0073576.g001
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expressed in bone cells with CX43 being the most abundant.
There is solid evidence for an important role of CX43 in skeletal
development and the function and survival of osteoblasts and
osteocytes [23,24,25,26]. Data from in vitro studies supported a
role for CX43 and gap junctional intracellular communication
during osteoblastic cell differentiation and coordinated cell
responsiveness [27,28]. In vivo studies demonstrated that
global ablation of Gja1 in mice results in delayed skeletal
ossification, craniofacial abnormalities and osteoblast
dysfunction [29,30]. Tissue-specific Gja1 ablation in
Figure 2.  Confirmatory sequencing.  Sanger sequencing to confirm exome sequencing data with a mutation in the CONNEXIN
43 gene GJA1 in position c.716G>A (p.Arg239Gln). Data shown for Family 1 (VIII5 proband; VIII3 unaffected sibling; VII5 and VII6
heterozygous parents), Family 2 (V1 proband, V4 affected cousin; IV26 and IV27afffected aunts; V2 and V3 unaffected cousins;
IV39 and IV40 heterozygous parents of V1; IV46 and IV47 heterozygous parents of V4) and Family 3 (III11 proband; III12
unaffected sibling; II8 and II9 heterozygous parents).
doi: 10.1371/journal.pone.0073576.g002
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osteoblasts results in accrual of a low peak bone mass and an
attenuated response to the anabolic effects of parathyroid
hormone (increase mineral apposition rate in response to PTH)
despite increased osteoblast numbers, which suggests a
functional defect in CX43-deficient bone-forming cells [31].
Osteoblast- and osteocyte-specific ablation of CX43 using an
osteocalcin-driven Cre-lox system resulted in bone loss due to
increased bone resorption and osteoclastogenesis [32]. Mice
lacking CX43 in osteocytes develop increased osteocyte
apoptosis and empty lacunae in cortical bone [25].
Further proof of the critical role of CX43 in skeletal biology
provides the identification of 65 mutations in GJA1 as the
cause of the predominantly autosomal dominant
oculodentodigital dysplasia (ODDD; MIM # 164200). ODDD is
characterized by craniofacial abnormalities, microphthalmia,
tooth defects, and hand and foot abnormalities such as fifth
finger camptodactyly, syndactyly of the fourth and fifth fingers,
and missing phalanges of the toes. Other skeletal
abnormalities include cranial hyperostosis, wide alveolar ridge
of the mandible as well as broad tubular bones [33,34,35,36].
The fact that the CMD patients described in this study do not
display the characteristic tooth defects, ocular involvement or
camptodactyly / syndactyly of ODDD strongly suggests that
their phenotype is consistent with CMD and not part of the
ODDD spectrum.
Another rare genetic disorder, Hallermann–Streiff syndrome
(HSS) is characterized by proportionate short stature,
hypotrichosis, congenital cataracts, malformation of cranial and
facial bones as well as dental anomalies (MIM #234100) and
shares several clinical characteristics with ODDD. Recently, a
single case with a homozygous CX43 gene mutation p. R76H
(c.227G>A) in a conserved region was found with overlapping
phenotypes of HSS/ODDD [37]. Some digital anomalies such
as type III syndactyly can be syndromic with ODDD although
isolated type III syndactyly has been attributed to a GJA1
mutation as well [38]. The only overlapping features of ODDD
patients with CMD patients harboring a Arg239Gln mutation in
GJA1 are cranial hyperostosis and widening of tubular bones.
Most of the autosomal dominant CX43 mutations for ODDD
that were studied in detail showed reduced channel function
inhibiting wild type CX43 in a dominant negative manner
[39,40]. It is therefore possible that the Arg239Gln mutation in
GJA1 also acts in a dominant negative manner by reducing the
function of other connexin homo- or oligomeres or of interacting
connection proteins. Recently, R76H and R33X mutations in
CX43 have been reported as the cause for autosomal
recessive ODDD by distinct mechanisms [41]. In vitro
experiments showed that the R76H mutant was able to form
functional gap junctions whereas the R33X mutant reduced the
connexin gap junction plaques.
In addition to its role as intercellular channel CX43 has been
shown to interact with intracellular structures and signaling
molecules such as β-arrestins for PTH receptor/cAMP signaling
in osteoblasts [42] and to affect cellular functions through its
cytoplasmic C-terminal domain [43].
Gap junctions can serve as anchoring locations for
microtubules thus regulating cellular activity associated with
microtubule function. Microtubules are one of the major
components of the cytoskeleton providing scaffolding,
sequestration and delivery functions. They are involved in
various signaling pathways such as Wnt, hedgehog (Hh),
nuclear factor kB (NF-κB) and mitogen activated protein kinase
K (MAPK) through diverse mechanisms [44,45,46,47,48,49].
These signaling pathways have also been implicated in skeletal
development and skeletal homeostasis.
The CX43 C-terminal cytoplasmic domain harbors a highly
conserved potential tubulin binding motif234 KGVKDRVKGK243
[22] thus mediating the TGF-β signaling pathway via Smad2/3,
which is a major player in osteoblast differentiation and
osteoblast-induced osteoclastogenesis [50]. CX43 competes
with Smad2/3 for binding to microtubules inducing release of
Smad2/3 from microtubules [51] and can increase phospho-
Figure 4.  Domain structure of CONNEXIN 43.  The CX43 protein consists of an intracellular amino acid domain (AT), four
transmembrane domains (TM), two extracellular loops and one intracellular loop. The novel CMD mutation is indicated as a red dot
in the carboxyl-terminal domain (CT).
doi: 10.1371/journal.pone.0073576.g004
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Smad2/3 accumulation in the nucleus leading to transcriptional
activation of target genes.
The R239Q mutation in our CMD patients is located within
this tubulin binding motif and we hypothesize that the amino
acid change may affect binding to microtubules. In this case
Smads may compete with microtubule binding and with their
translocation to the nucleus thus altering the expression of
osteoblastic genes regulated by Smads.
Therefore, it is possible that the CX43 mutation causes CMD
by either changing the tubulin binding site or by affecting signal
transduction events via alteration of transport properties of gap
junctions/hemichannels.
Conclusions
In summary, our exome sequencing study identified a novel
disease gene for the autosomal recessive form of
craniometaphyseal dysplasia. The causative variant in the
CONNEXIN 43 gene GJA1 results in a disease-specific CMD
phenotype demonstrating that CMD is a genetically
heterogeneous disorder. It will be interesting to study any
discernible clinical differences of the recessive CX43 form of
CMD to the autosomal dominant form caused by ANKH
mutations once more patients with CX43 mutations have been
identified for this very rare craniotubular disorder. It is also
remains to be investigated whether any mechanistic
interactions between CX43 and ANKH exist.
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